The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032.

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

MAID is currently legal in 10 states and Washington, D.C., but eight other states are considering similar laws this year.

The genes included those involved in the function of energy-producing mitochondria, lipid and iron metabolism, and the ...

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

A diet containing foods that quickly raise blood sugar is associated with slower amyotrophic lateral sclerosis (ALS ... In a previous study involving 304 sporadic ALS patients from the ALS Multicenter ...

Many people living with multiple sclerosis (MS) experience speech issues. With MS, you can develop persistent speech difficulties, or you might have speech problems that come and go. You may find ...

A correct diagnosis is important to ensure proper treatment. Multiple sclerosis (MS) is an autoimmune neurological condition that destroys the protective coating (myelin) that surrounds the nerves.

Multiple sclerosis (MS) hip pain and knee soreness are very common problems. Joint issues are usually due to a nerve-related or muscle-related manifestation of MS rather than degeneration of cartilage ...

Detailed price information for Promis Neurosciences Inc (PMN-Q) from The Globe and Mail including charting and trades.